top of page
  • Writer's pictureDLRG

Cell-free biotech could drive COVID-19 therapeutics

Updated: Feb 7, 2021

Platform could produce new antiviral drugs more than 10 times faster

A biomanufacturing company spun out of the DLRG is seeking to rapidly translate an antibody therapy against COVID-19 by using cell-free biotechnology based on glycoengineered bacteria. And it could scale up the production 10 times faster than conventional methods. The company, SwiftScale Biologics, was co-founded by Matt DeLisa, the William L. Lewis Professor of Engineering in the Robert F. Smith School of Chemical and Biomolecular Engineering, and his longtime collaborator, Michael Jewett, a professor of chemical and biological engineering at Northwestern University.

To learn more, see the stories:

52 views0 comments


Commenting has been turned off.
bottom of page